在活性化疗期间使用Mavacamten治疗有症状的阻塞性多变性心肌病
Juan Caro-Codón1, Silvia Valbuena-López1, Ismael Ghanem Cañete2
1Cardiology Department, La Paz University Hospital, IdiPaz Research Institute, Madrid, Spain.
JACC. Case reports
|November 28, 2025
概括
马瓦卡门在接受结肠癌化疗的患者中有效治疗了阻塞性多变性心肌病变 (oHCM). 这种心脏髓酶抑制剂改善了症状和生活质量,尽管存在活跃的恶性瘤.
科学领域:
- 心脏瘤学是一门专业.
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在患有活跃恶性瘤的患者中,阻塞性缩性心肌病 (oHCM) 治疗尚未得到充分证实.
- 心脏肌肉酶抑制剂代表了oHCM的新型治疗类.
研究的目的:
- 评估mavacamten在患有oHCM和正在接受化疗的活跃结肠癌的患者中的安全性和有效性.
主要方法:
- 一名68岁的患有结肠癌和症状性oHCM的女性患者接受了mavacamten治疗.
- 监测了心血管参数,包括左心室外流通道 (LVOT) 梯度,NYHA功能类和NT-proBNP水平.
- 患者继续接受化疗,同时接受Mavacamten治疗.
主要成果:
- 马瓦卡门在4周内迅速将LVOT梯度从115 mm Hg降低到10 mm Hg.
- 患者的NYHA功能类改进到I,NT-proBNP水平显著下降.
- 化疗安全地继续,患者维持了9个月的临床改善.
结论:
- 马瓦卡门在这种oHCM患者中证明了安全性和有效性,该患者患有正在接受化疗的活跃恶性瘤.
- 心脏髓素抑制显示出在管理复杂的并发症,如oHCM和癌症方面的潜力.
- 马瓦卡门可以改善oHCM患者的生活质量,即使是那些患有活跃癌症的人.
相关概念视频
Cardiomyopathy III: Hypertrophic Cardiomyopathy
374
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
374
Cardiomyopathy V: Interprofessional Care
314
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
314
Cardiomyopathy II: Dilated Cardiomyopathy
447
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
447
Mitral Stenosis III: Medical Management
223
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
223
Cardiomyopathy IV: Restrictive Cardiomyopathy
431
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
431
Myocarditis III: Medical Management
162
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
162


